NCT04498767招募中不适用
Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial
European Organisation for Research and Treatment of Cancer - EORTC26 个研究点 分布在 7 个国家目标入组 200 人开始时间: 2021年6月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 26
- 主要终点
- Overall survival
研究概览
简要总结
This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers.
Patients will be randomized in a 1:1 ratio between current standard of care treatment vs. standard of care treatment + SBRT to all sites of known metastatic disease.
The primary objective of this trial is to assess if the addition of stereotactic body radiotherapy (SBRT) to standard of care treatment improves overall survival (OS) as compared to standard of care treatment alone in patients with rare oligometastatic cancers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.
- •Controlled primary tumour, defined as:
- •at least 3 months since original tumour treated definitively, with no progression at primary site
- •Total number of oligometastases of 1-5 including:
- •Brain metastases amenable to radiosurgery or fractionated stereotactic radiotherapy patient who had neurosurgical resection before trial inclusion are allowed and resected brain metastases count to the total number of oligometastases
- •All sites of disease can be safely treated based on the judgement of an experienced radiation oncologist
- •ECOG score 0-2
- •Life expectancy > 6 months
- •Age 18 or older
- •Before patient randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
排除标准
- •Primary cancer of prostate, breast, lung or colorectal
- •Serious medical comorbidities precluding radiotherapy:
- •These include interstitial lung disease in patients requiring thoracic radiation, Crohn's disease in patients where the GI tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy and connective tissue disorders such as lupus or scleroderma.
- •For patients with liver metastases, moderate/severe liver dysfunction (Child Pugh B or C)
- •Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein. For patients treated previously with radiation, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in the RTQA Guidelines. All such cases should be discussed with one of the study coordinators
- •Brain metastases only, without extra-cerebral metastases
- •Malignant pleural effusion, malignant ascites, meningeal carcinomatosis and peritoneal carcinomatosis
- •Maximum size of 6 cm for lesions outside the brain, except:
- •Bone metastases over 5 cm may be included, if in the opinion of the local radiation oncologist it can be treated safely (e.g. rib, scapula, pelvis)
- •Clinical or radiologic evidence of symptomatic spinal cord compression. Patients can be eligible if surgical resection has been performed, but the surgical site counts toward the total of up to 3 metastases.
- •Metastatic disease that invades any of the following: GI tract (including oesophagus, stomach, small or large bowel), mesenteric lymph nodes, or disseminated skin metastases and lymphangiosis
- •Pregnant or breast feeding women
- •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial
结局指标
主要结局
Overall survival
时间窗: 7.5 years from first patient in
Overall survival is the time interval from the date of randomization to the date of death whatever the cause of death. Patients who are alive are censored at the last date known to be alive.
次要结局
- Time to disease progression(9 years from first patient in)
- Time to development of new metastatic lesions(9 years from first patient in)
- Disease-specific survival(9 years from first patient in)
- Health-related quality of life evaluated using self-administered EORTC QLQ-C30 questionnaires(9 years from first patient in)
- Adverse events graded according to the National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTCAE) version 5.0(9 years from first patient in)
- Progression-free survival(9 years from first patient in)
- Time to development of polymetastatic disease(9 years from first patient in)
- Health-related quality of life evaluated using self-administered EQ-5D-5L questionnaires(9 years from first patient in)
研究者
研究点 (26)
Loading locations...
相似试验
招募中
3 期
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerLocally Advanced Lung Non-Small Cell CarcinomaStage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8NCT05624996NRG Oncology474
撤回
2 期
A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line ChemotherapyCarcinoma, Non-Small-Cell LungNCT02623595Wuhan University
Unknown
2 期
SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line ChemotherapyLung Cancer MetastaticNCT02976740The First Affiliated Hospital of Xiamen University48
终止
3 期
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)Non-Small Cell Lung CancerNCT03924869Merck Sharp & Dohme LLC448
招募中
3 期
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)Renal Cell Carcinoma (Kidney Cancer)Kidney Cancer MetastaticRenal Cell Carcinoma MetastaticNCT06726421Sun Yat-sen University252